Ascendis Pharma A/S
243.37USD
+0.3800 (+0.16%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ASND.
| In EUR M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|
| Revenue | 339 | 247 | 248 | 214 | 158 |
| Cost of Revenue | 28 | 18 | 24 | 22 | 31 |
| Gross Profit | 312 | 229 | 224 | 191 | 127 |
| Operating Income | 220 | 25 | 6 | 11 | -53 |
| Net Income | 207 | 629 | -34 | -61 | -39 |
| EPS (Diluted) | €2.83 | €9.75 | -€0.55 | -€1.00 | -€0.82 |
Source: Yahoo Finance (limited history)